Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal

References

• Ponikowski P, Anker SD, AlHabib KF, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4–25.
   PubMedGoogle Scholar
• Coelho R, Ramos S, Prata J, et al. Heart failure and health related quality of life. Clin Pract Epidemiol Ment Health. 2005;1:19.
   PubMedGoogle Scholar
• Schocken DD, Arrieta MI, Leaverton PE, et al. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 1992;20(2):301–306.
   PubMed Web of Science ®Google Scholar
• Hoes AW, Mosterd A, Grobbee DE. An epidemic of heart failure? Recent evidence from Europe. Eur Heart J. 1998;19(Suppl):L:L2-9.
   PubMedGoogle Scholar
• Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J. 1994;72(2 Suppl):S3–9.
   PubMedGoogle Scholar
• Ceia F, Fonseca C, Mota T, et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail. 2002;4(4):531–539.
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Estatística IP. Censos 2011: resultados definitivos - Portugal. 2011.
   Google Scholar
• Gouveia M, Ascenção R, Fiorentino F, et al. The current and future burden of heart failure in Portugal. ESC Heart Fail. 2019;6(2):254-261. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Fiorentino F, Ascenção R, Gouveia M, et al. The cost of illness of heart failure in Portugal. Value Health. 2017;20(9):A610.
   PubMedGoogle Scholar
• Yancy CW, Januzzi JL Jr., Allen LA, et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2018;71(2):201–230.
   PubMed Web of Science ®Google Scholar
• Szucs TD, Goedde M, Berger K, et al. [Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study]. Schweiz Med Wochenschr. 1997;127(29–30):1234–1241.
   PubMedGoogle Scholar
• Antonanzas Villar F, Anton Botella F, Echevarria Echarri L. [Cost-effectiveness analysis of the treatment with enalapril of chronic heart failure in Spain]. Gac Sanit. 1996;10(54):135–142.
   PubMedGoogle Scholar
• Glick H, Cook J, Kinosian B, et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. J Card Fail. 1995;1(5):371–380.
   PubMedGoogle Scholar
• Paul SD, Kuntz KM, Eagle KA, et al. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med. 1994;154(10):1143–1149.
   PubMedGoogle Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
   PubMed Web of Science ®Google Scholar
• Jjv M, Trueman D, Hancock E, et al. Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart. 2018;104(12):1006–1013.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the american college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. J Am Coll Cardiol. 2017;70(6):776–803.
   PubMed Web of Science ®Google Scholar
• EMA. EU SPC Entresto, last update: 22/06/2018.2018.
   Google Scholar
• INFARMED. Orientações metodológicas para estudos de avaliação económica de medicamentos; 1998.
   Google Scholar
• Instituto Nacional de Estatística IP. Tábua Completa de Mortalidade para Portugal - 2011-2013; 2014.
   Google Scholar
• Instituto Nacional de Estatística IP. Estatísticas da Saúde – 2013; 2015.
   Google Scholar
• INFARMED. Infomed; 2016.
   Google Scholar
• Administração Central do Sistema de Saúde ACSS IP.
   Google Scholar
• Ministério da Saúde. Portaria 234/2015 de 7 de agosto. (Diário da República n.º 153/2015, Série I de 2015-08-07, 2015).
   Google Scholar
• Gandjour A, Ostwald DA. Sacubitril/Valsartan (LCZ696): a novel treatment for heart failure and its estimated cost effectiveness, budget impact, and disease burden reduction in Germany. PharmacoEconomics. 2018;36(10):1285–1296.
   PubMed Web of Science ®Google Scholar
• Ramos IC, Versteegh MM, de Boer RA, et al. Cost effectiveness of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan for patients with chronic heart failure and reduced ejection fraction in the Netherlands: a country adaptation analysis under the former and current dutch pharmacoeconomic guidelines. Value Health. 2017;20(10):1260–1269.
   PubMed Web of Science ®Google Scholar
• van der Pol S, Degener F, Postma MJ, et al. An economic evaluation of sacubitril/valsartan for heart failure patients in the Netherlands. Value Health. 2017;20(3):388–396.
   PubMed Web of Science ®Google Scholar
• D’Angiolella LS, Cortesi PA, Pitotti C, et al. Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context. Eur J Heart Fail. 2017;19(11):1551–1553.
   PubMed Web of Science ®Google Scholar
• Ademi Z, Pfeil AM, Hancock E, et al. Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction. Swiss Med Wkly. 2017;147:w14533.
   PubMed Web of Science ®Google Scholar
• Sandhu AT, Ollendorf DA, Chapman RH, Pearson SD, Heidenreich PA. Cost-effectiveness of sacubitril-valsartan in patients with heart failure with reduced ejection fraction. Ann Intern Med. 2016;165(10):681–689.
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Emergência (INEM). Relatório de Atividades e Contas 2012; 2013.
   Google Scholar
• Comissão para a Reavaliação da Rede Nacional de Emergência e Urgência C. Reavaliação da Rede Nacional de Emergência/Urgência. (Fev 2012. Reviewed in 2014).
   Google Scholar